Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin

• References

• 1 Dardik R, Loscalzo J, Eskaraev R. et al. Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler Thromb Vasc Biol 2005; 25: 526-32.
• 2 Anwar R, Minford A, Gallivan L. et al. Delayed umbilical bleeding – a presenting feature for factor XIII deficiency: clinical features, genetics, and management. Pediatrics 2002; 109: E32.
• 3 Board PG, Losokowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev 1993; 7: 229-42.
• 4 Born P, Lippl F, Ulm K. et al. Reduced levels of coagulation factor XIII in patients with advanced tumor disease. Hepatogastroenterology 2000; 47: 194-8.
• 5 Loswsky MS, Miloszowsky KJ. Factor XIII. Br J Haematol 1977; 37: 1-5.
• 6 Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev 1993; 7: 229-42.
• 7 Seitz R, Duckert F, Lopaciuk MD. ETRO working party on factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Semin Thromb Haemost 1996; 22: 415-8.
• 8 Jennings I, Kitchen S, Woods AL. et al. Problems realting to the laboratory diagnosis of factor XIII deficiency: a NEQAS study. J Thromb Haemost 2003; 1: 2603-8.
• 9 Kaspar CK. Laboratory tests for factor VIII inhibitors, their variation, significance and interpretation. Blood Coagul Fibrinolysis 1991; 2: 7-10.
• 10 Ahmad F, Solymoss S, Poon MC. et al. Characterization of an acquired Ig Ginhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus. Br J Haematol 1996; 93: 700-3.
• 11 Lorand L, Velasco PT, Hill JM. et al. Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against factor XIII. Thromb Haemost 2002; 88: 919-23.
• 12 McDevitt NB, McDonagh J, Taylor HL. et al. Anacquired inhibitor to factor XIII. Arch Intern Med 1972; 130: 772-7.
• 13 McDonagh J.. Structure and function of factor XIII. Colman RW, Hirsh J, Marder VJ, Saltzman EW. eds. Hemostasis and Thrombosis: Basic principles and clinical practice, 3th edn Philadelphia PA: JB Lippncott Co; 1994: 301
• 14 Nijenhuis AVM, van Bergeijk L, Huijgens PC. et al. Acquired factor XIII deficiency due to an inhibitor: a case report and reviewof the literature. Haematologica 2004; 89: 14-9.
• 15 van Beek EJ, Peters M, ten Cate JW. Factor VIII inhibitor associated with ciprofloxacin. Thromb Haemost 1993; 69: 403.
• 16 Miesbach W, Voigt J, Peetz D. et al. Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin. Med Klin 2003; 98: 339-43.
• 17 Daly HM, Carson PJ, Smith JK. Intracerebral hemorrhage due to acquired factor XIII inhibitor – successful response to factor XIII concentrate. Blood Coagul Fibrinolysis 1991; 2: 507-14.
• 18 Tosetto A, Rodeghiero F, Gatto E. et al. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. Am J Hematol 1995; 48: 34-9.
• 19 Schwartz RS, Gabriel DA, Aledort LM. et al. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitor with high-dose intravenous gammaglobin. Blood 1995; 86: 797-804.
• 20 Stasi R, Brunetti M, Stipa E. et al. Selective Bcell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
• 21 Stasi R, Pagano A, Stipa E. et al. Rituximab chimeric anti-CD20 monoclonal treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-7.
• 22 Quartier P, Brethon B, Philippet P. et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358: 1511-3.